Indivior Pharmaceuticals (INDV) EBITDA Margin (2024 - 2026)
Indivior Pharmaceuticals' EBITDA Margin was 47.23% in Q2 2026, up 22.73 percentage points from 24.50% a year earlier and up 3.38 percentage points from the prior quarter.
Powered by 
Analysis
Indivior Pharmaceuticals (INDV) EBITDA Margin (2024 - 2026) Analysis & Trends
On a trailing twelve-month basis, Indivior Pharmaceuticals' EBITDA Margin was 32.28% through Jun 30, 2026, up 12.44 percentage points year-over-year; for FY2025, it came in at 21.95%, up 17.41 percentage points from FY2024.
- EBITDA Margin shows a four-year change of -6.87 percentage points (FY2021 to FY2025).
- In earlier years, EBITDA Margin was 4.55% in FY2024 (+17.08 pp), -12.53% in FY2023 (-5.76 pp), -6.77% in FY2022 (-35.59 pp) and 28.82% in FY2021.
- The Q2 2026 figure marks the highest quarterly EBITDA Margin in data going back to Q1 2024.
- Compared with a year earlier, EBITDA Margin has increased for five straight quarters, with an average year-over-year change of +18.30 percentage points over the last six quarters.
- Per Business Quant data, INDV's EBITDA Margin in the three quarters before Q2 2026 was 43.85% (Q1 2026), 23.18% (Q4 2025) and 14.65% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,165.22 Bn | 1,133.81 Bn | 19.71 Bn | 53.49% |
| 2 | Johnson & Johnson | 646.28 Bn | 566.14 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 503.17 Bn | 476.28 Bn | 12.70 Bn | 49.01% |
| 4 | Merck | 365.23 Bn | 319.60 Bn | 12.21 Bn | 6.02% |
| 5 | Novartis Ag | 302.66 Bn | 266.65 Bn | 11.24 Bn | - |
| 6 | Astrazeneca | 267.39 Bn | 241.08 Bn | 12.86 Bn | 33.11% |
| 7 | Amgen | 241.61 Bn | 197.01 Bn | 7.24 Bn | 46.01% |
| 8 | Gilead Sciences | 194.67 Bn | 168.86 Bn | 6.22 Bn | -124.26% |
| 9 | Pfizer | 172.91 Bn | 119.55 Bn | 10.94 Bn | 39.16% |
| 10 | Indivior Pharmaceuticals | 4.18 Bn | 3.14 Bn | 294.00 Mn | 47.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.23% |
| Mar 31, 2026 | 43.85% |
| Dec 31, 2025 | 23.18% |
| Sep 30, 2025 | 14.65% |
| Jun 30, 2025 | 24.50% |
| Mar 31, 2025 | 25.94% |
| Dec 31, 2024 | 17.06% |
| Sep 30, 2024 | 12.70% |
| Jun 30, 2024 | -38.80% |
| Mar 31, 2024 | 28.17% |
API Access
Indivior Pharmaceuticals EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INDV&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "INDV", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=INDV&period=max&api_key=YOUR_API_KEY");
const data = await res.json();